ClinicaliQ Trial Snapshot
- A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis — Recruiting • Phase III • Diabetes / Metabolic • NCT06215716.
- Efruxifermin tested against placebo in 1,650 patients with liver scarring from fatty liver disease (stages 2-3, non-cirrhotic).
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects. Conditions: NASH With Fibrosis, MASH With Fibrosis Interventions: Efruxifermin, Placebo Lead Sponsor: Akero Therapeutics, Inc Planned Enrollment: 1650 participants